Core Viewpoint - The announcement indicates that the controlling shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., has released a portion of its pledged shares in Jinhai Biological, totaling 33,051,000 shares [2] Company Summary - Jinhai Biological has received notification from its controlling shareholder regarding the release of pledged shares [2] - The number of shares released from pledge amounts to 33,051,000 [2]

Core Viewpoint - Jinhe Biotechnology Co., Ltd. has received a notification from its controlling shareholder, Inner Mongolia Jinhe Holdings Co., Ltd., regarding the release of part of its pledged shares on September 5, 2023 [1] Group 1 - A total of 33,051,000 shares were released from pledge, accounting for 15.08% of the shares held by Jinhe Holdings and 4.28% of the company's total share capital [1] - As of the announcement date, Jinhe Holdings has cumulatively pledged 107,190,000 shares, which represents 48.90% of its held shares [1] - The cumulative pledged shares with concerted actors amount to 107,190,000 shares, accounting for 41.84% of their held shares, indicating no risk of forced liquidation and no impact on the company's operations [1]

证券代码：002688 证券简称：金河生物 公告编号：2025-083 金河生物科技股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份解除质押。具体事项如下： 漫、王晓英所持质押股份情况如下： 股东名称 持股数量 （股） 持股 比例 累计质押 数量（股） 占其所 持股份 比例 占公司 总股本 比例 已质押股份 情况 未质押股份 情况 已质押 股份限 售和冻 结数量 占已 质押 股份 比例 未质押 股份限 售和冻 结数量 占未 质押 股份 比例 金河控股 219,195,570 28.41% 107,190,000 48.90% 13.89% 0 0 0 0 路牡丹 25,964,401 3.36% 0 0 0 0 0 0 0 | 王志军 | 2,318,931 | 0.30% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | --- | ...

Market Overview - The animal health sector increased by 1.25% on September 5, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Yongshun Biological (839729) closed at 10.82, up 4.14% with a trading volume of 44,500 shares and a turnover of 47.80 million yuan [1] - Shilian Biological (688098) closed at 11.76, up 3.16% with a trading volume of 114,100 shares and a turnover of 132 million yuan [1] - Other notable performers include: - Houfeng Holdings (002141): closed at 3.96, up 2.33% [1] - KQ Biological (688526): closed at 18.00, up 2.16% [1] - Dayu Biological (871970): closed at 10.25, up 2.09% [1] Capital Flow - The animal health sector experienced a net outflow of 37.19 million yuan from institutional investors, while retail investors saw a net inflow of 13.24 million yuan [2] - Notable capital flows include: - Shilian Biological: net inflow of 500.11 thousand yuan from institutional investors [3] - Houfeng Holdings: net inflow of 91.15 thousand yuan from retail investors [3] - KQ Biological: net outflow of 297.54 thousand yuan from institutional investors [3]

Core Viewpoint - The controlling shareholder of Jinhe Biological, Inner Mongolia Jinhe Holdings Co., Ltd., has completed its share reduction plan, selling a total of 22,563,100 shares, which accounts for 3% of the company's total share capital after excluding repurchased shares [1][2]. Group 1: Share Reduction Details - The share reduction plan was initially announced on May 17, 2025, with the reduction period set from June 10, 2025, to September 9, 2025 [1]. - The reduction was executed through two methods: a block trade and centralized bidding, with a maximum of 7,521,130 shares (1% of total share capital) sold via centralized bidding and 15,042,259 shares (2% of total share capital) sold via block trade [1]. - The average selling price for the block trade was 6.81 yuan, while the average price for the centralized bidding was 7.26 yuan, resulting in a total cash-out amount of approximately 157,039,161 yuan [2]. Group 2: Shareholding Changes - Prior to the reduction, the controlling shareholder and its concerted actors held a total of 278,744,052 shares, representing 37.0615% of the total share capital after excluding repurchased shares [2]. - After the reduction, the total shares held by the controlling shareholder and its concerted actors decreased to 256,180,952 shares, which is 34.0615% of the total share capital after excluding repurchased shares [2]. - Specifically, Inner Mongolia Jinhe Holdings now holds 219,195,570 shares, accounting for 29.1440% of the total share capital after excluding repurchased shares [2]. Group 3: Source of Reduced Shares - The shares being reduced originated from the previous controlling shareholder, Inner Mongolia Jinhe Construction and Installation Co., Ltd., due to a division of the company, which included shares acquired before the initial public offering and through non-public offerings, as well as shares from capital increases and stock distributions [3]. Group 4: Completion of the Plan - As of the announcement date, the share reduction plan has been fully implemented [4].

Core Viewpoint - The controlling shareholder of Jinhe Biological Technology Co., Ltd., Inner Mongolia Jinhe Holdings Co., Ltd., plans to reduce its shareholding by a total of 22,563,389 shares, accounting for 3% of the company's total share capital, through various trading methods from June 10, 2025, to September 9, 2025 [1]. Shareholder Reduction Details - The reduction was completed between August 11, 2025, and September 1, 2025, with a total of 22,563,100 shares sold, also representing 3% of the company's total share capital after excluding repurchased shares [2]. - The reduction was executed through two methods: 15,042,100 shares via block trading at an average price of 6.81 yuan per share, and 7,521,000 shares via centralized bidding at an average price of 7.26 yuan per share [3]. - Prior to the reduction, the controlling shareholder and its concerted actors held a total of 278,744,052 shares, which was 34.0615% of the total share capital after excluding repurchased shares [4]. Shareholding Structure Post-Reduction - After the reduction, the controlling shareholder's stake decreased to 241,758,670 shares, representing 32.1439% of the total share capital [4]. - The total shareholding of the controlling shareholder and its concerted actors post-reduction is 256,180,952 shares, which is 33.1998% of the total share capital [4]. - The shareholding structure includes 271,305,120 shares with no restrictions and 7,438,932 shares with restrictions [4].

Core Viewpoint - The controlling shareholder, Jinhai Holdings, has completed its share reduction plan, impacting the company's total share capital [1] Summary by Relevant Sections Share Reduction Details - Jinhai Holdings reduced its stake by a total of 22,563,100 shares from August 11, 2025, to September 1, 2025 [1] - This reduction represents 3% of the company's total share capital after excluding repurchased shares [1]

Core Viewpoint - The controlling shareholder of Jinhe Biological has completed its share reduction plan, selling a total of 22.5631 million shares, which represents 3% of the company's total share capital after excluding repurchased shares [1] Group 1 - The share reduction took place between August 11, 2025, and September 1, 2025 [1] - The shares were sold through block trading and centralized bidding methods [1]

证券代码：002688 证券简称：金河生物 公告编号：2025-082 金河生物科技股份有限公司 关于控股股东减持计划完成暨减持结果的公告 控股股东内蒙古金河控股有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 减持的股份来源： 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 17 日披露 了《关于控股股东减持股份预披露的公告》，公司控股股东内蒙古金河控股有限 公司（以下简称"金河控股"）计划 2025 年 6 月 10 日至 2025 年 9 月 9 日通过 集中竞价交易、大宗交易方式减持公司股份合计不超过 22,563,389 股，即不超 过公司总股本（总股本按剔除公司回购专用账户中的股份数量 19,521,410 股计 算，下同）的 3%。其中，以集中竞价方式减持公司股份不超过 7,521,130 股（占 总股本比例 1%），以大宗交易方式减持公司股份不超过 15,042,259 股（占总股 本比例 2%）。 公司于 2025 年 8 月 13 日披露了《关于控股股东及一致 ...

Summary of Key Points Core Viewpoint - The controlling shareholder, Jinhe Holdings, has reduced its stake in Jinhe Biological through block trading and centralized bidding, indicating a strategic shift in ownership structure [1] Group 1: Shareholding Changes - Jinhe Holdings reduced its stake by 15,042,100 shares through block trading at an average price of 6.81 CNY per share, accounting for 2.0000% of the total share capital after excluding repurchased shares [1] - Additionally, 7,521,000 shares were sold through centralized bidding at an average price of 7.26 CNY per share, representing 1.0000% of the total share capital [1] - The total reduction amounted to 22,563,100 shares, which is 3.0000% of the total share capital after excluding repurchased shares [1] Group 2: Remaining Shareholding - After the reduction, the controlling shareholder and its concerted parties hold a total of 256,000,000 shares, which constitutes 34.0615% of the total share capital after excluding repurchased shares [1]